The JCSO Interview

New myeloma drugs improve response and extend survival

An interview series in which Editors of The Journal of Community and Supportive Oncology discuss the latest research and best practices with experts in the clinical and supportive care of patients with cancer.

Submit a paper here


 

In this interview, Dr David Henry, the Editor-in-Chief of The Journal of Community and Supportive Oncology, and Dr Ken Anderson, the Kraft Family Professor of Medicine at Harvard Medical School and an international thought leader and investigator in myeloma, discuss three cases of patients with myeloma that are indicative of the remarkable therapeutic advances in oncology in general, and in myeloma in particular.

Listen to the podcast below

Recommended Reading

An unusual case of primary cardiac prosthetic valve-associated lymphoma
MDedge Hematology and Oncology
Meeting the potential of immunotherapy: new targets provide rational combinations
MDedge Hematology and Oncology
Immunotherapies shape the treatment landscape for hematologic malignancies
MDedge Hematology and Oncology
New myeloma drugs improve response and extend survival
MDedge Hematology and Oncology
Durable response to pralatrexate for aggressive PTCL subtypes
MDedge Hematology and Oncology
First CAR T-cell therapy approvals bolster booming immunotherapy market
MDedge Hematology and Oncology
Study links communication, outcomes in cancer
MDedge Hematology and Oncology
Mogamulizumab prolongs PFS in CTCL
MDedge Hematology and Oncology
Auto-HSCT linked to higher AML, MDS risk
MDedge Hematology and Oncology
Group releases new CLL guidelines
MDedge Hematology and Oncology